litlas
Log inCreate account

Michele Baccarani

Active 1979–2022

182
Papers
51,251
Citations
111
h-index
182
i10-index

Citations

Citations per year for Michele Baccarani1979: 29 citations1980: 1 citations1982: 7 citations1983: 5 citations1984: 6 citations1985: 5 citations1986: 4 citations1987: 5 citations1988: 5 citations1989: 1 citations1990: 11 citations1991: 2 citations1992: 4 citations1993: 8 citations1994: 6 citations1995: 7 citations1996: 7 citations1997: 9 citations1998: 17 citations1999: 15 citations2000: 22 citations2001: 25 citations2002: 40 citations2003: 146 citations2004: 148 citations2005: 161 citations2006: 214 citations2007: 360 citations2008: 357 citations2009: 461 citations2010: 361 citations2011: 438 citations2012: 452 citations2013: 406 citations2014: 414 citations2015: 484 citations2016: 433 citations2017: 330 citations2018: 287 citations2019: 1,144 citations2020: 1,222 citations2021: 1,099 citations2022: 737 citations2023: 404 citations2024: 863 citations2025: 315 citations2026: 4 citations1981: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,760 citing papers, 24.4% of this breakdownItaly: 1,049 citing papers, 9.3% of this breakdownGermany: 873 citing papers, 7.7% of this breakdownUnited Kingdom: 764 citing papers, 6.8% of this breakdownFrance: 692 citing papers, 6.1% of this breakdownChina: 580 citing papers, 5.1% of this breakdownSpain: 373 citing papers, 3.3% of this breakdownNetherlands: 337 citing papers, 3% of this breakdownAustralia: 323 citing papers, 2.9% of this breakdownCanada: 323 citing papers, 2.8% of this breakdownSwitzerland: 301 citing papers, 2.7% of this breakdownJapan: 257 citing papers, 2.3% of this breakdown
0%24.4%Other 23.6%

Institutions

Fields

  • Medicine77%
  • Biochemistry, Genetics and Molecular Biology11.4%
  • Immunology and Microbiology7%
  • Neuroscience1.5%
  • Computer Science0.8%
  • Chemistry0.4%
  • Other1.9%

Topics

  • Chronic Myeloid Leukemia Treatments11.9%
  • Chronic Lymphocytic Leukemia Research6.9%
  • Acute Myeloid Leukemia Research5.5%
  • Eosinophilic Disorders and Syndromes4.8%
  • Multiple Myeloma Research and Treatments3.7%
  • Acute Lymphoblastic Leukemia research3.6%
  • Other63.6%

Coauthors

All papers

Open in search
  1. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Authors: Andreas Hochhaus, Michele Baccarani, Richard T. Silver, CA Schiffer, Jane F. Apperley, Francisco Cervantes, R E Clark, J. E. Cortes, Michael W. Deininger, François Guilhot, Henrik Hjorth‐Hansen, Timothy P. Hughes, J. Janssen, Hagop M. Kantarjian, D. W. Kim, Richard A. Larson, J. H. Lipton, F.-X. Mahon, Jiří Mayer, Franck E. Nicolini, D Niederwieser, Fabrizio Pane, Jerald P. Radich, Delphine Réa, Johan Richter, G Rosti, Philipe Rousselot, Giuseppe Saglio, Susanne Saußele, Simona Soverini, J. L. Steegmann, Anna Turkina, Andrey Zaritskey, R. Hehlmann - Leukemia 2020 cited by 1,510

  2. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

    Authors: Andreas Hochhaus, Richard A. Larson, François Guilhot, Jerald P. Radich, Susan Branford, Timothy P. Hughes, Michele Baccarani, Michael W. Deininger, Francisco Cervantes, Satoko Fujihara, Christine-Elke Ortmann, Hans D. Menssen, Hagop Kantarjian, Stephen G. O’Brien, Brian Druker - New England Journal of Medicine 2017 cited by 1,259

  3. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Authors: Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz, Philipp le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Réa, Michele Baccarani, Martin C. Müller, Carlo Gambacorti‐Passerini, Siu‐Fun Wong, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John M. Goldman, Neil P. Shah, Hagop M. Kantarjian - New England Journal of Medicine 2013 cited by 1,124

  4. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

    Authors: Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Réa, Michele Baccarani, Martin C. Müller, Carlo Gambacorti‐Passerini, Stephanie Lustgarten, Victor M. Rivera, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Hagop M. Kantarjian - Blood 2018 cited by 583

  5. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

    Authors: Jörge E. Cortes, Giuseppe Saglio, Hagop M. Kantarjian, Michele Baccarani, Jiřı́ Mayer, Concepción Boqué, Neil P. Shah, Charles Chuah, Luís Casanova, Brigid Bradley-Garelik, George Manos, Andreas Hochhaus - Journal of Clinical Oncology 2016 cited by 946

  6. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

    Authors: Brian Druker, François Guilhot, Stephen G. O’Brien, Insa Gathmann, Hagop M. Kantarjian, Norbert Gattermann, Michael W. Deininger, Richard T. Silver, John M. Goldman, Richard M. Stone, Francisco Cervantes, Andreas Hochhaus, Bayard L. Powell, Janice Gabrilove, Philippe Rousselot, Josy Reiffers, Jan J. Cornelissen, Timothy P. Hughes, Hermine Agis, Thomas Fischer, Gregor Verhoef, John D. Shepherd, Giuseppe Saglio, Aloïs Gratwohl, Johan Lanng Nielsen, Jerald P. Radich, Bengt Simonsson, Kerry Taylor, Michele Baccarani, Charlene So, Laurie Letvak, Richard A. Larson - New England Journal of Medicine 2006 cited by 3,481

  7. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

    Authors: Stephen G. O’Brien, François Guilhot, Richard A. Larson, Insa Gathmann, Michele Baccarani, Francisco Cervantes, Jan J. Cornelissen, Thomas Fischer, Andreas Hochhaus, Timothy P. Hughes, Klaus Lechner, Johan Lanng Nielsen, Philippe Rousselot, Josy Reiffers, Giuseppe Saglio, John D. Shepherd, Bengt Simonsson, Aloïs Gratwohl, John M. Goldman, Hagop M. Kantarjian, Kerry Taylor, Gregor Verhoef, Ann E. Bolton, Renaud Capdeville, Brian Druker - New England Journal of Medicine 2003 cited by 3,565

  8. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

    Authors: Hagop M. Kantarjian, Neil P. Shah, Andreas Hochhaus, Jörge E. Cortes, Sandip Shah, Manuel Ayala, Beatriz Moiraghi, Zhixiang Shen, Jiřı́ Mayer, Ricardo Pasqüini, Hirohisa Nakamae, Françoise Huguet, Concepción Boqué, Charles Chuah, Eric Bleickardt, M. Brigid Bradley‐Garelik, Chao Zhu, Ted P. Szatrowski, Д. А. Шапиро, Michele Baccarani - New England Journal of Medicine 2010 cited by 1,582

  9. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Authors: Michele Baccarani, Michael Deininger, Gianantonio Rosti, Andreas Hochhaus, Simona Soverini, Jane F. Apperley, Francisco Cervantes, Richard E. Clark, Jörge E. Cortes, François Guilhot, Henrik Hjorth‐Hansen, Timothy P. Hughes, Hagop M. Kantarjian, Dong‐Wook Kim, Richard A. Larson, Jeffrey H. Lipton, François-Xavier Mahon, Giovanni Martinelli, Jiřı́ Mayer, Martin Müller, Dietger Niederwieser, Fabrizio Pane, Jerald P. Radich, Philippe Rousselot, Giuseppe Saglio, Susanne Saußele, Charles A. Schiffer, Richard T. Silver, Bengt Simonsson, Juan-Luis Steegmann, John M. Goldman, Rüdiger Hehlmann - Blood 2013 cited by 1,989

  10. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

    Authors: Robin Foà, Antonella Vitale, Marco Vignetti, Giovanna Meloni, Anna Guarini, Maria Stefania De Propris, Loredana Elia, Francesca Paoloni, Paola Fazi, Giuseppe Cimino, Francesco Nobile, Felicetto Ferrara, Carlo Castagnola, Simona Sica, Pietro Leoni, Eliana Zuffa, Claudio Fozza, Mario Luppi, Anna Candoni, Ilaria Iacobucci, Simona Soverini, Franco Mandelli, Giovanni Martinelli, Michele Baccarani, on behalf of the GIMEMA Acute Leukemia Working Party - Blood 2011 cited by 461

  11. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients

    Authors: Antonio Curti, Loredana Ruggeri, Alessandra D’Addio, Andrea Bontadini, Elisa Dan, Maria Rosa Motta, Sara Trabanelli, Valeria Giudice, Elena Urbani, Giovanni Martinelli, Stefania Paolini, Fiorenza Fruet, Alessandro Isidori, Sarah Parisi, Giuseppe Bandini, Michele Baccarani, Andrea Velardi, Roberto M. Lemoli - Blood 2011 cited by 402

  12. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

    Authors: Markus Pfirrmann, Michele Baccarani, Susanne Saußele, Joëlle Guilhot, Francisco Cervantes, G.J. Ossenkoppele, Verena Hoffmann, Fausto Castagnetti, Joerg Hasford, Rüdiger Hehlmann, Bengt Simonsson - Leukemia 2015 cited by 300

  13. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

    Authors: Jeffrey H. Lipton, Charles Chuah, Agnès Guerci‐Bresler, Gianantonio Rosti, David Simpson, Sarit Assouline, Gabriel Étienne, Franck E. Nicolini, Philipp le Coutre, Richard E Clark, Leif Stenke, David Andorsky, Vivian G. Oehler, Stephanie Lustgarten, Victor M. Rivera, Timothy Piers Clackson, Frank G. Haluska, Michele Baccarani, Jörge E. Cortes, François Guilhot, Andreas Hochhaus, Timothy P. Hughes, Hagop M. Kantarjian, Neil P. Shah, Moshe Talpaz, Michael Deininger - The Lancet Oncology 2016 cited by 259

  14. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

    Authors: Hagop M. Kantarjian, Neil P. Shah, Jörge E. Cortes, Michele Baccarani, M B Agarwal, María Soledad Undurraga, Jianxiang Wang, Juan Julio Kassack Ipiña, Dong‐Wook Kim, Michinori Ogura, Carolina Pavlovsky, Christian Junghanß, Jorge Milone, Franck E. Nicolini, Tadeusz Robak, Jan Van Droogenbroeck, Edo Vellenga, M. Brigid Bradley‐Garelik, Chao Zhu, Andreas Hochhaus - Blood 2011 cited by 605

  15. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

    Authors: Elena Zamagni, Francesca Patriarca, Cristina Nanni, Beatrice Anna Zannetti, Emanuela Englaro, Annalisa Pezzi, Paola Tacchetti, Silvia Buttignol, Giulia Perrone, Annamaria Brioli, Lucia Pantani, Carolina Terragna, Francesca Carobolante, Michele Baccarani, Renato Fanin, Stefano Fanti, Michèle Cavo - Blood 2011 cited by 533

  16. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

    Authors: Juan Luis Steegmann, Michele Baccarani, Massimo Breccia, Luis Felipe Casado, Valentín García‐Gutiérrez, Andreas Hochhaus, D.-W. Kim, T D Kim, H. Jean Khoury, P. Le Coutre, Jiří Mayer, Dragana Milojković, Kimmo Porkka, Delphine Réa, Gianantonio Rosti, Susanne Saußele, R. Hehlmann, Richard E. Clark - Leukemia 2016 cited by 475

  17. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25− into CD25+ T regulatory cells

    Authors: Antonio Curti, Simona Pandolfi, Barbara Valzasina, Michela Aluigi, Alessandro Isidori, Elisa Ferri, Valentina Salvestrini, Giuseppina Bonanno, Sergio Rutella, Ilaria Durelli, Alberto L. Horenstein, Francesca Fiore, Massimo Massaia, Mario P. Colombo, Michele Baccarani, Roberto M. Lemoli - Blood 2006 cited by 388

  18. BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

    Authors: Matthew S. Zabriskie, Christopher A. Eide, Srinivas K. Tantravahi, Nadeem A. Vellore, Johanna Estrada, Franck E. Nicolini, H. Jean Khoury, Richard A. Larson, Marina Konopleva, Jörge E. Cortes, Hagop M. Kantarjian, Elias Jabbour, Steven M. Kornblau, Jeffrey H. Lipton, Delphine Réa, Leif Stenke, Gisela Barbany, Thoralf Lange, Juan Carlos Hernández‐Boluda, Gert J. Ossenkoppele, Richard D. Press, Charles Chuah, Stuart L. Goldberg, Meir Wetzler, François-Xavier Mahon, Gabriel Étienne, Michele Baccarani, Simona Soverini, Gianantonio Rosti, Philippe Rousselot, Ran Friedman, Marie Deininger, Kimberly R. Reynolds, William L. Heaton, Anna M. Eiring, Anthony D. Pomicter, Jamshid S. Khorashad, Todd W. Kelley, Riccardo Baron, Brian Druker, Michael W. Deininger, Thomas O’Hare - Cancer Cell 2014 cited by 366

  19. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6

    Authors: Marina Ratta, Francesco Fagnoni, Antonio Curti, Rosanna Vescovini, Paolo Sansoni, Barbara Oliviero, Miriam Fogli, Elisa Ferri, G. Robustelli della Cuna, S Tura, Michele Baccarani, Roberto M. Lemoli - Blood 2002 cited by 447

  20. IKZF1 (Ikaros) Deletions in BCR-ABL1 –Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report

    Authors: Giovanni Martinelli, Ilaria Iacobucci, Clelia Tiziana Storlazzi, Marco Vignetti, Francesca Paoloni, Daniela Cilloni, Simona Soverini, Antonella Vitale, Sabina Chiaretti, Giuseppe Cimino, Cristina Papayannidis, Stefania Paolini, Loredana Elia, Paola Fazi, Giovanna Meloni, Sergio Amadori, Giuseppe Saglio, Fabrizio Pane, Michele Baccarani, Robin Foà - Journal of Clinical Oncology 2009 cited by 322

  21. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview

    Authors: for the International BCR-ABL Study Group, Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, Gianantonio Rosti, Simona Soverini, Ali Albeer, Markus Pfirrmann - Leukemia 2019 cited by 138

  22. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

    Authors: Mark J. Levis, Farhad Ravandi, Eunice S. Wang, Maria R. Baer, Alexander E. Perl, Steven Coutré, Harry P. Erba, Robert K. Stuart, Michele Baccarani, Larry D. Cripe, Martin S. Tallman, Giovanna Meloni, Lucy A. Godley, Amelia Langston, Sergio Amadori, Ian D. Lewis, Arnon Nagler, Richard M. Stone, Karen Yee, Anjali S. Advani, Dan Douer, W Wiktor-Jędrzejczak, Gunnar Juliusson, Mark R. Litzow, Stephen H. Petersdorf, Miguel Á. Sanz, Hagop M. Kantarjian, Takashi Sato, Lothar Tremmel, Debra M. Bensen-Kennedy, Donald Small, B. Douglas Smith - Blood 2011 cited by 399

  23. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

    Authors: H. Jean Khoury, Jörge E. Cortes, Hagop M. Kantarjian, Carlo Gambacorti‐Passerini, Michele Baccarani, Dong‐Wook Kim, Andrey Zaritskey, Athena Countouriotis, Nadine Besson, Eric Leip, Virginia Kelly, Tim H. Brümmendorf - Blood 2012 cited by 318

  24. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

    Authors: Fabio Efficace, Michele Baccarani, Massimo Breccia, Giuliana Alimena, Gianantonio Rosti, Francesco Cottone, Giorgio La Nasa, Claudia Baratè, Antonella Russo Rossi, Giuseppe Fioritoni, Luigia Luciano, Diamante Turri, Bruno Martino, Francesco Di Raimondo, Melissa Dabusti, Micaela Bergamaschi, Pietro Leoni, Maria Pina Simula, Luciano Levato, Stefano Ulisciani, Dino Veneri, Simona Sica, Alessandro Rambaldi, Marco Vignetti, Franco Mandelli, for GIMEMA - Blood 2011 cited by 256